Published • loading... • Updated
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Summary by MarketBeat
2 Articles
2 Articles
MarketBeatReposted by 
BizToc
BizTocExelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Exelixis (NASDAQ:EXEL) executives outlined plans to continue expanding the CABOMETYX franchise while preparing for a potential launch of zanzalintinib, or zanza, in colorectal cancer later this year. Speaking at a Wells biotech session, Chief Financial Officer Chris Senner said the company is worki
·Sioux Falls, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
